Aspire Biopharma shares surge 26.03% intraday after signing CDMO agreement with Microsize to develop sublingual aspirin for heart attack treatment.

Aspire Biopharma surged 26.03% intraday following the announcement of a strategic collaboration with Microsize, a leading CDMO, to advance its lead drug candidate—a 162 mg sublingual aspirin powder for suspected acute myocardial infarction. The partnership aims to optimize the drug’s formulation for an upcoming clinical trial and a planned Section 505(b)(2) New Drug Application submission by late 2026. The clinical study will assess the drug’s efficacy compared to the current standard of care, potentially positioning it as a faster-acting alternative with fewer side effects. The interim CEO emphasized the agreement as a critical milestone for the company’s U.S.-based innovation and regulatory strategy, reinforcing investor confidence in the drug’s development timeline and commercial potential.